Scancell Holdings

Validating and de-risking of multiple opportunities

15 Feb 2018 / Corporate research

Scancell is a clinical-stage biotechnology company developing two distinct flexible cancer immunotherapy platforms, each with broad applications: ImmunoBody is a DNA vaccine that stimulates high-avidity anti-tumour CD8+ T-cells for use as a monotherapy or in combination with checkpoint inhibitors(CPIs); Moditope targets modified antigens and stimulates powerful anti-tumour CD4+ T-cell responses for use in advanced and hard-to-treat cancers. Both technologies have been externally validated recently through partnership deals with Cancer Research UK (CRUK; ImmunoBody SCIB2) and BioNTech (Moditope), providing significant endorsements.

  • Strategy: Scancell is developing two proprietary immuno-oncology platforms that target cancer cells directly to produce potent T-cell responses. Both technologies are highly flexible, potentially targeting many types of cancer. The initial aim is to complete proof-of-concept trials in multiple indications.
  • ImmunoBody: After exceptional five-year survival data in a proof-of-concept trial in late-stage melanoma patients and evidence of tumour rejection, Scancell will advance both SCIB1 (melanoma) and SCIB2 (with CRUK in lung cancer) in combination trials with a CPI. Headline data should start to emerge from 1H’19.
  • Moditope: This technology exploits the normal immune response to stressed cells in order to eradicate cancer cells through immunisation. The clinical lead,
    Modi-1, is expected to enter a Phase I/II proof-of-concept trial, initially in triple negative breast cancer, ovarian cancer and sarcoma in 1H calendar 2019.
  • Risks: Scancell is an early-stage drug development company carrying a high risk that a product may fail in clinical trials. Its focus on cancer immunotherapy is extremely exciting, but it is a competitive field. The novelty of its technologies has been endorsed through recent partnerships with CRUK and BioNTech.
  • Investment summary: Scancell is trading on an EV of ca.£34m, compared with a cumulative investment of £29m to get the company to where it is today, which is low compared to its relevant peers. Scancell’s proprietary technologies are in the ‘hot’ area of immuno-oncology and targeting markets of significant unmet medical need. Recent deals have demonstrated the price that big pharma is willing to pay for validated assets in the field.
Download the full report

Request a meeting

If you'd like to be introduced to the team at Scancell Holdings, get in touch.

Request a meeting